UNSPSC 51343502: Cidofovir

This classification denotes an antiviral agent with the molecular formula C8H14N3O6P.2H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, JIL713Q00N chemically known as phosphonic acid, ((2-(4-amino-2-oxo-1(2h)-pyrimidinyl)-1-(hydroxymethyl)ethoxy)methyl)-, dihydrate, (s)- but generally known as cidofovir, which bears US NIH Compound Identifier 60613. European Medicines Agency schedules Cidofovir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06257MIG.

UNSPSC 51343502 Cidofovir is a Commodity-level code for a specific antiviral pharmaceutical product. State and local procurement activity tagged to this code shows little relevant recent solicitation — the two most recent opportunities in the source are for other pharmaceuticals (doxycycline, ciprofloxacin, naloxone, and drug deactivation systems) rather than cidofovir itself, suggesting either sparse direct demand for cidofovir under this code or inconsistent code assignment in state and local systems. The scope of work when cidofovir is procured by state and local bodies would be emergency stockpile replenishment or disease-response preparedness, as cidofovir is a narrow-spectrum antiviral used primarily in biodefense and select infectious-disease protocols.

State and local health departments and counties are the primary issuing bodies when pharmaceuticals are solicited under related codes. The two recent records show the Illinois Department of Public Health managing a $2,999,999.11 three-year piggyback pharmaceutical contract through the MMCAP Infuse cooperative purchasing vehicle (awarded to Chartwell Rx LLC as of August 28, 2026), and Seminole County, Florida issuing an IFB for naloxone and drug deactivation systems with quarterly deliveries to the Seminole County Community Health Building (response deadline July 26, 2023). Geographic activity appears concentrated in the Midwest and Southeast, though the limited volume of cidofovir-specific opportunities prevents a robust regional characterization. Firms pursuing this code should monitor state health department emergency preparedness and disease-response solicitations, particularly through cooperative purchasing consortia like MMCAP and regional health networks, where pharmaceutical stockpile contracts typically appear.